Kevin Carroll

1.9k total citations
32 papers, 1.4k citations indexed

About

Kevin Carroll is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Statistics and Probability. According to data from OpenAlex, Kevin Carroll has authored 32 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 7 papers in Statistics and Probability. Recurrent topics in Kevin Carroll's work include Prostate Cancer Treatment and Research (21 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Statistical Methods in Clinical Trials (7 papers). Kevin Carroll is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Statistical Methods in Clinical Trials (7 papers). Kevin Carroll collaborates with scholars based in United Kingdom, United States and Belgium. Kevin Carroll's co-authors include Peter Iversen, Teuvo L.J. Tammela, C. Tyrrell, Stefan Michiels, Marc Buyse, Tomasz Burzykowski, M. C. Chamberlain, John Anderson, Amir V. Kaisary and Manfred P. Wirth and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Society of Nephrology and The Journal of Urology.

In The Last Decade

Kevin Carroll

30 papers receiving 1.3k citations

Peers

Countries citing papers authored by Kevin Carroll

Since Specialization

Citations

This map shows the geographic impact of Kevin Carroll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Carroll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Carroll more than expected).

Fields of papers citing papers by Kevin Carroll

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Carroll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Carroll. The network helps show where Kevin Carroll may publish in the future.

Co-authorship network of co-authors of Kevin Carroll

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Carroll. A scholar is included among the top collaborators of Kevin Carroll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Carroll. Kevin Carroll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial 2025 ·Kidney International Reports ·Vlado Perkovic, Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll, Chee Kay Cheung, Vladimı́r Tesař, Hernán Trimarchi, Muh Geot Wong, Hong Zhang, Jing Xia, (unknown), (unknown), Jeffrey Hafkin, Dana V. Rizk	0
2	A practical guide to the appropriate analysis of eGFR data over time: A simulation study 2024 ·Pharmaceutical Statistics ·Todd DeVries, Kevin Carroll, (unknown)	0
3	Natural History of IgA Nephropathy: Analysis of a UK National RaDaR IgA Nephropathy Cohort 2021 ·Journal of the American Society of Nephrology ·Jonathan Barratt, Moin A. Saleem, Fiona Braddon, Kevin Carroll, Ping He, Bruce M. Hendry, (unknown), David Pitcher, Retha Steenkamp, Neil Turner, Daniel P. Gale	1
4	Individual- and trial-level surrogacy in colorectal cancer 2008 ·Statistical Methods in Medical Research ·Marc Buyse, Tomasz Burzykowski, Stefan Michiels, Kevin Carroll	57
5	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer 2007 ·Journal of Clinical Oncology ·Marc Buyse, Tomasz Burzykowski, Kevin Carroll, Stefan Michiels, Daniel J. Sargent, Langdon L. Miller, Gary Elfring, Jean‐Pierre Pignon, Pascal Piedbois	267
6	Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program 2004 ·Urology ·Peter Iversen, Manfred P. Wirth, William A. See, David G. McLeod, Ira Klimberg, Donald M. Gleason, Gerald W. Chodak, James E. Montie, C. Tyrrell, D. M. A. WALLACE, K.P.J. Delaere, (unknown), Teuvo L.J. Tammela, Jan‐Erik Johansson, Tom Morris, Kevin Carroll	12
7	A re‐assessment of the role of combined androgen blockade for advanced prostate cancer 2004 ·British Journal of Urology ·Laurence Klotz, Paul Schellhammer, Kevin Carroll	61
8	BICALUTAMIDE (150 MG) VERSUS PLACEBO AS IMMEDIATE THERAPY ALONE OR AS ADJUVANT TO THERAPY WITH CURATIVE INTENT FOR EARLY NONMETASTATIC PROSTATE CANCER: 5.3-YEAR MEDIAN FOLLOWUP FROM THE SCANDINAVIAN PROSTATE CANCER GROUP STUDY NUMBER 6 2004 ·The Journal of Urology ·Peter Iversen, Jan‐Erik Johansson, Pär Lodding, O Lukkarinen, P.I. Lundmo, Peter Klarskov, Teuvo L.J. Tammela, İlker Taşdemir, Tom Morris, Kevin Carroll, (unknown)	76
9	180 Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non-metastatic prostate cancer: Updated analysis at a median 5.4 years' follow-up 2004 ·European Urology Supplements ·Peter Iversen, Donald S.A. McLeod, (unknown), Manfred P. Wirth, (unknown), (unknown), Kevin Carroll	5
10	Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia 2004 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Teuvo L.J. Tammela, August Bakke, Pär Lodding, L. Goedhals, P. Van Erps, Tom A. Boon, C. van de Beek, Swen‐Olof Andersson, Tom Morris, Kevin Carroll	67
11	810: Bicalutamide 150 MG Alone or as Adjuvant to Standard Care Significantly Improves Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer (Median 5.4 Years' Follow-Up) 2004 ·The Journal of Urology ·William A. See, Peter Iversen, David G. McLeod, Manfred P. Wirth, Thomas Morris, Kevin Carroll	2
12	Is prostate-specific antigen progression a surrogate for objective clinical progression in early prostate cancer? 2004 ·Journal of Clinical Oncology ·Don Newling, Kevin Carroll, Thomas Morris	4
13	1062: Bicalutamide 150 mg in Addition to Standard Care Significantly Improves Prostate Specific Antigen Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer: Median 5.4 Years' follow-up 2004 ·The Journal of Urology ·William A. See, Peter Iversen, David G. McLeod, Manfred P. Wirth, Kevin Carroll, Thomas Morris, Clive Morris	2
14	Immediate treatment with bicalutamide reduces the risk of disease progression in early non-metastatic prostate cancer irrespective of primary therapy 2002 ·European Urology Supplements ·William A. See, Manfred Wirth, David G. McLeod, Peter Iversen, Bo‐Eric Persson, Kevin Carroll	3
15	Prophylactic breast irradiation significantly reduces the incidence of bicalutamide-induced gynaecomastia 2002 ·European Urology Supplements ·(unknown), Thomas Morris, Kevin Carroll	6
16	Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: 2002 ·The Journal of Urology ·William A. See, Manfred P. Wirth, David G. McLeod, Peter Iversen, Ira Klimberg, Donald M. Gleason, Gerald W. Chodak, James E. Montie, C. Tyrrell, D. M. A. WALLACE, K.P.J. Delaere, Sigmund Vaage, Teuvo L.J. Tammela, O Lukkarinen, Bo‐Eric Persson, Kevin Carroll, Geert J.C.M. Kolvenbag	3
17	Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? 2001 ·Prostate Cancer and Prostatic Diseases ·(unknown), Peter Iversen, CJ Tyrrell, Kevin Carroll, Thomas Morris	30
18	Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? 2000 ·Urology ·Michael F. Sarosdy, Paul F. Schellhammer, (unknown), Kevin Carroll, Geert J.C.M. Kolvenbag	15
19	BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP 2000 ·The Journal of Urology ·Peter Iversen, C. Tyrrell, Amir V. Kaisary, John Anderson, Hendrik Van Poppel, Teuvo L.J. Tammela, M. C. Chamberlain, Kevin Carroll, I. Melezínek	265
20	Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years 1998 ·Urology ·Peter Iversen, C. Tyrrell, Amir V. Kaisary, John Anderson, Luc Baert, Teuvo L.J. Tammela, M. C. Chamberlain, Kevin Carroll, (unknown), G. Blackledge	125

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact